ClinicalTrials.gg

Program

sofetabart mipitecan

Also written as “Sofe-M” and “Sofetabart Mipitecan”.

Its studies are mostly in Ovarian Neoplasms, led by Eli Lilly.

Furthest: phase 3, since Oct 7, 20252 company-led studies, 2 open or runningNext primary completion: Nov 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly22 open or runningphase 3since Oct 7, 2025Apr 30, 2024Nov 2028phase 3 · NCT07213804
  • Named in Eli Lilly’s own pipeline as Sofetabart Mipitecan, phase 3, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 30, 2024First study: phase 1 study in Ovarian NeoplasmsFirst studyNCT06400472 · 575 planned · United States, Australia, France and more
  2. Oct 7, 2025Phase 3 study in Ovarian NeoplasmsNCT07213804 · 1,630 planned · United States, Australia, Austria and more

Ahead

  1. Nov 2028Primary completion: phase 3 study in Ovarian NeoplasmsNCT07213804
  2. Jun 2029Primary completion: phase 1 study in Ovarian NeoplasmsNCT06400472

TargetBeta

“An antibody-drug conjugate (ADC) composed of a Fc-silenced, humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting folate receptor alpha (FRa; FolRa; FOLR1) linked, via a dipeptide cleavable linker and a polysarcosine hydrophobicity masking agent, to the camptothecin analog and topoisom…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a Fc-silenced, humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting folate receptor alpha (FRa; FolRa; FOLR1) ”NCIt, by rule

Other programs on FOLR1

ProgramCompanyFurthest phaseStudies
mirvetuximab soravtansineruleAbbViephase 315
rinatabart sesutecanruleGenmabphase 39
torvutatug samrotecanAstraZenecaphase 35
opugotamig olatansineAbbViephase 22
Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901AbbViephase 11
Anti-FRa/Anti-CD3 Bispecific TCE NTB-928ruleteneoseven-incphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07213804Ovarian Neoplasms · United States, Australia, Austria and more3RecruitingNov 20281,630
NCT06400472Ovarian Neoplasms · United States, Australia, France and more1RecruitingJun 2029575

How it is read

Names in the registry

  • “Sofe-M”, 1 entry
  • “Sofetabart Mipitecan”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.